Sanofi/Regeneron's dupilumab has broad success in asthma
This article was originally published in Scrip
Executive Summary
Partners Sanofi and Regeneron Pharmaceuticals are to move their anti-IL-4/IL-13 monoclonal antibody dupilumab into Phase III trials in moderate to severe uncontrolled asthma following positive results across its Phase IIb study population, which showed the drug had utility not just for the subset of patients with high eosinophils.